Currently available software tools that support the AD, UP and CE domains are far from simple.
Of these ORFs, 95 encode GH domains, 4 encode PL domains, 18 encode CE domains, and 4 encode both GH and CE domains (Supporting Information: Tables S1, S2, and S3).
Additionally, several GT, PL and CE domains were identified as relevant (eSVMCAZY_A: PL1, PL11 and CE5, "eSVMCAZY_B: CE5; eSVMCAZY_a: GT39, PL1 and CE2, eSVMCAZY_b: none).
In the UK Sunbeamm" study [ 32], all five CHIP-CE domains and its total score managed to differentiate between atomoxetine treatment and standard current therapy.
Also in the SUNBEAM study, where all 5 CHIP-CE domains differentiated between the atomoxetine and SCT groups, only one of the 6 domains of the Harter scale, "scholastic competence" succeeded to differentiate between the groups.
No statistically significant differences were seen in the other CHIP-CE domains, Satisfaction, Resilience, and Comfort, which all include subdomains related to bodily functioning, i.e., areas usually not primarily affected in patients with ADHD.
Interestingly, the present results regarding the changes in CHIP-CE domains are consistent with the results of another placebo-controlled study, investigating HRQL in Spanish children and adolescents with ADHD (14).
These baseline conditions of the UK study were also reflected in lower baseline values for some of the CHIP-CE domains, e.g., in t scores for Satisfaction and Risk avoidance as low as ~33 35, and ~20, respectively.
In this Spanish study, only the CHIP-CE domains Achievement and Risk Avoidance, as assessed by parents improved significantly more in atomoxetine-treated patients compared to patients treated with placebo.
An improvement for both treatment arms was seen for all CHIP-CE domains including the total score, with a statistically significantly greater improvement in atomoxetine-treated patients in the primary measure, the CHIP-CE total score, and in the five domain scores.
